Search

Your search keyword '"V. Di Martino"' showing total 63 results
Start Over Author "V. Di Martino" Topic hepatology
63 results on '"V. Di Martino"'

3. AF.87 RESIST-HCV CRITERIA ARE ABLE TO RULE OUT ESOPHAGEAL VARICES PROGRESSION IN PATIENTS WITH HCV CIRRHOSIS TREATED BY DIRECT-ACTING ANTIVIRAL AGENTS(DAAS)

Author

M. Licata, Antonio Craxì, Y. Abdel Hadi, L. Crapanzano, V. Di Martino, S. Petta, L. Di Marco, V. Di Marco, C. Cammà, F. Simone, and Vincenza Calvaruso

Subjects
medicine.medical_specialty, Cirrhosis, Esophageal varices, Hepatology, business.industry, Internal medicine, Gastroenterology, medicine, In patient, medicine.disease, business, Direct acting
Published
2021
Full Text
View/download PDF

5. PNPLA3 rs738409 C >G variant is associated with a higher risk of liver fibrosis progression assessed by FIB-4 and stiffness by fibroscan in patients with non-alcoholic fatty liver disease

Author

S. Petta, Rosaria Maria Pipitone, Grazia Pennisi, Stefania Grimaudo, V. Di Marco, Antonio Craxì, Federica Spatola, C. Cammà, and V. Di Martino

Subjects
medicine.medical_specialty, Hepatology, business.industry, Liver fibrosis, Fatty liver, Gastroenterology, Non alcoholic, Disease, medicine.disease, Internal medicine, medicine, In patient, business
Published
2020
Full Text
View/download PDF

6. Impact of postoperative events on the occurrence of anastomotic biliary strictures after liver transplantation

Author

Alexandre Doussot, J. Magnin, B. Paquette, Célia Turco, Bruno Heyd, Marianne Latournerie, Anne Minello, C. Clerc, Claire Vanlemmens, P. Georges, Zaher Lakkis, and V. Di Martino

Subjects
medicine.medical_specialty, Hepatology, business.industry, medicine.medical_treatment, Gastroenterology, Medicine, Anastomosis, Liver transplantation, business, Surgery
Published
2021
Full Text
View/download PDF

8. Safety of sofosbuvir-based regimens after liver transplantation longitudinal assessment of renal function in the prospective ANRS CO23 CUPILT study

Author

Rodolphe Anty, Alpha Diallo, Vincent Leroy, L. D’Alteroche, Jean Charles Duclos-Vallée, Claire Fougerou-Leurent, Christophe Duvoux, Vincent L.M. Esnault, P. Perré, François Habersetzer, Audrey Coilly, Aurelie Veislinger, Nassim Kamar, V. Di Martino, Emilie Rossignol, Valérie Canva, Maryline Debette-Gratien, Carole Cagnot, François Durand, Didier Samuel, Clémence M. Canivet, Danielle Botta-Fridlund, H. Montialoux, V. de Ledinghen, Christine Silvain, Camille Besch, Jérôme Dumortier, Albert Tran, Guillaume Favre, Pauline Houssel-Debry, Georges Philippe Pageaux, S. Radenne, H. Danjou, Sébastien Dharancy, Fabio Conti, Pascal Lebray, Armando Abergel, Christophe Moreno, Centre Hospitalier Universitaire de Nice (CHU Nice), Centre méditerranéen de médecine moléculaire (C3M), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA), Laboratoire de PhysioMédecine Moléculaire (LP2M), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), CHU Pontchaillou [Rennes], Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Physiopathologie du cancer du foie, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Grenoble, Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), CHU Toulouse [Toulouse], Hôpital Claude Huriez [Lille], CHU Lille, Hôpital Edouard Herriot [CHU - HCL], Service d'Hépato-Gastro-Entérologie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Strasbourg, CHU Marseille, CHU Rouen, Normandie Université (NU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Interactions Virus-Hôte et Maladies Hépatiques, Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Virologie, CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand, CHU Limoges, ANRS France Recherche Nord & sud Sida-hiv hépatites, Hôpital Lapeyronie [Montpellier] (CHU), Université Nice Sophia Antipolis (1965 - 2019) (UNS), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), and Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)

Subjects
medicine.medical_specialty, Sofosbuvir, Hepatitis C virus, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Urology, Renal function, Hepacivirus, 030230 surgery, Liver transplantation, medicine.disease_cause, Kidney, Cohort Studies, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Recurrence, Ribavirin, Medicine, Humans, Pharmacology (medical), Longitudinal Studies, Prospective Studies, Renal Insufficiency, Chronic, Aged, Creatinine, Hepatology, business.industry, Gastroenterology, Middle Aged, Hepatitis C, 3. Good health, Liver Transplantation, medicine.anatomical_structure, chemistry, Cohort, 030211 gastroenterology & hepatology, Female, business, medicine.drug, Glomerular Filtration Rate
Abstract

International audience; Background In liver transplant recipients with hepatitis C virus recurrence, there is concern about renal safety of sofosbuvir-based regimens. Changes in serum creatinine or in the estimated glomerular filtration rate (eGFR) under treatment are used to look for possible renal toxicity. However, serum creatinine and eGFR are highly variable. Aim To analyse renal function trajectory with numerous assays of serum creatinine over a long period of time. Methods In a multicentre cohort of 139 patients, the eGFR was obtained from serum creatinine using the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation. Slopes of eGFR were defined as a change in eGFR during a period divided by time. Pre-treatment, on-treatment and post-treatment periods were 9 months, 3-9 months and 4.5 months. Interactions between eGFR slopes and the pre-treatment eGFR, use of ribavirin or mycophenolate mofetil, and stage of fibrosis were addressed. On-treatment eGFR slopes were separated in tertiles. Pre- and post-treatment eGFR slopes were compared globally and according to tertiles. Results The post-treatment eGFR slope was significantly better than pre-treatment eGFR slope (+0.18 (IQR -0.76 to +1.32) vs -0.11 (IQR -1.01 to +0.73) mL/min/1.73 m(2)/month, P=0.03) independently of the pre-treatment eGFR (P=0.99), ribavirin administration (P=0.26), mycophenolate mofetil administration (P=0.51) and stage of fibrosis (F3 and F4 vs lower stages, P=0.18; F4 vs lower stages, P=0.08; F4 Child-Pugh B and C vs lower stages, P=0.38). Tertiles of on-treatment eGFR slopes were -1.71 (IQR -2.54 to -1.48), -0.78 (IQR -1.03 to -0.36) and +0.75 (IQR +0.28 to +1.47) mL/min/1.73 m(2)/month. Pre- and post-treatment eGFR slopes were not significantly different according to tertiles (respectively, P=0.34, 0.08, 0.73). Conclusion The eGFR varies during treatment and gives a confusing picture of the renal safety of sofosbuvir-based regimens. In contrast, longitudinal assessment of the eGFR shows a rising trajectory over longer time, meaning that these therapies are safe for the kidneys in our cohort of liver transplant recipients.

Published
2018
Full Text
View/download PDF

9. Impact of Cytomegalovirus infection on the outcome of patients with cirrhosis: a preliminary study

Author

Jean-Baptiste Bour, Laurent Andreoletti, Vanessa Cottet, Jean-Louis Jouve, J.-J. Raabe, Elisabeth Monnet, Gérard Thiéfin, Samira Fafi-Kremer, Morgan Faivre, Séverine Valmary-Degano, Georges Herbein, François Habersetzer, Michel Doffoel, Brice Malve, Hélène Barraud, V. Di Martino, Evelyne Schvoerer, Jean-Pierre Bronowicki, Christine Binquet, C. Richou, Patrick Hillon, Service d'Hépatologie, Hôpital Jean Minjoz, Centre Hospitalier Universitaire de Besançon, Université de Franche Comté, Centre Hospitalier Régional Universitaire Hôpital Jean Minjoz [Besançon], Centre d'Investigation Clinique 1432 (Dijon) - Epidemiologie Clinique/Essais Cliniques ( CIC-EC ), Université de Bourgogne ( UB ) -Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Laboratoire de sérologie-virologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Laboratoire d'anatomie pathologique [Besancon], Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Jean Minjoz-Université de Franche-Comté ( UFC ), Unité de virologie médicale [Reims], Hôpital Robert Debré, Service d'Hépato-gastro-entérologie [CHR Metz-Thionville], Centre hospitalier régional Metz-Thionville ( CHR Metz-Thionville ), Service de Virologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ), Laboratoire de Virologie [Strasbourg], Service d'Ophtalmologie (CHU de Dijon), Centre d'Investigation Clinique 1432 (Dijon) - Module Plurithématique : Périnatalité Cancérologie Handicap et Ophtalmologie ( CIC-P803 ), Université de Bourgogne ( UB ) -Direction Générale de l'Organisation des Soins (DGOS)-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Service d'Hépato-Gastro-Entérologie (CHU de Dijon), Service d'hépato-gastroentérologie, CHU Strasbourg-Hopital Civil, Centre d'Investigation Clinique de Besançon ( CICB ), Etablissement Français du Sang Bourgogne Franche-Comté-Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Franche-Comté ( UFC ), Service d'hépatogastroentérologie (CHU Reims), Centre Hospitalier Universitaire de Reims ( CHU Reims ), Service d'Hépatologie [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre d'Investigation Clinique 1432 (Dijon) - Epidemiologie Clinique/Essais Cliniques (CIC-EC), Université de Bourgogne (UB)-Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service d'Anatomie pathologique [CHRU Besançon], Centre hospitalier régional Metz-Thionville (CHR Metz-Thionville), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre d'Investigation Clinique 1432 (Dijon) - Module Plurithématique : Périnatalité Cancérologie Handicap et Ophtalmologie (CIC-P803), Institut National de la Santé et de la Recherche Médicale (INSERM)-Direction Générale de l'Organisation des Soins (DGOS)-Université de Bourgogne (UB), Centre d'Investigation Clinique de Besançon (Inserm CIC 1431), Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])

Subjects
Clinical aspects, Cirrhosis and its complications, 0303 health sciences, medicine.medical_specialty, Cirrhosis, Hepatology, business.industry, Clinical aspects, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, medicine.disease, Gastroenterology, Outcome (game theory), 3. Good health, Cytomegalovirus infection, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, 030211 gastroenterology & hepatology, [ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Cirrhosis and its complications, business, ComputingMilieux_MISCELLANEOUS, 030304 developmental biology
Abstract

International audience

Published
2017
Full Text
View/download PDF

10. Should we keep using Ribavirin to Treat Hepatitis C Recurrence after Liver Transplantation? Results from the CO23 ANRS Cupilt Study

Author

Jean Charles Duclos-Vallée, F. Durand, Valérie Canva, V. Di Martino, Abou Diallo, G.-P. Pageaux, S. Radenne, Claire Fougerou-Leurent, Emilie Rossignol, Aurelie Veislinger, Pauline Houssel-Debry, Rodolphe Anty, H. Danjou, Vincent Leroy, Christophe Duvoux, L. D’Alteroche, C. Silvain, Audrey Coilly, V. de Ledinghen, Camille Besch, Caroline Jezequel, Maryline Debette-Gratien, A. Rohel, François Habersetzer, Nassim Kamar, H. Montialoux, Jérôme Dumortier, Armando Abergel, Christophe Moreno, Fabio Conti, Pascal Lebray, Danielle Botta-Fridlund, P. Perré, Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Service d'Hépatologie, Hôpital Henri Mondor, AP-HP, Créteil, France., Hôpital Henri Mondor, Hôpital Paul Brousse, Département d'hépatologie, Hospices Civils de Lyon (HCL), Institut de médecine moléculaire de Rangueil (I2MR), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-IFR150-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Services de Maladies de l'Appareil Digestif, Hôpital Claude Huriez, Centre Hospitalier Universitaire de Lille, Lille, France, Hôpital Claude Huriez [Lille], CHU Lille-CHU Lille, CHU Pitié-Salpêtrière [AP-HP], Service d'hépato-gastroentérologie, Hôpital de la Conception, AP-HM, Marseille, Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Hôpital Erasme [Bruxelles] (ULB), Faculté de Médecine [Bruxelles] (ULB), Université libre de Bruxelles (ULB)-Université libre de Bruxelles (ULB), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Laboratoire Inflammation, Tissus épithéliaux et Cytokines (LITEC), Université de Poitiers, Service de Transplantation, Centre Hospitalier Universitaire de Strasbourg, Centre Hospitalier Universitaire de Strasbourg (CHU de Strasbourg ), CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand, Unité de la recherche fondamentale et clinique sur l' hépatite virale, France Recherche Nord & Sud Asdi-VIH Hépatites, Agence Nationale de Recherche sur le Sida, Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université de Toulouse (UT)-Université de Toulouse (UT)- Institut Fédératif de Recherche Bio-médicale Institution (IFR150)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
medicine.medical_specialty, Hepatology, business.industry, medicine.medical_treatment, Ribavirin, [SDV]Life Sciences [q-bio], Hepatitis C, 030230 surgery, Liver transplantation, medicine.disease, Gastroenterology, 3. Good health, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, chemistry, Internal medicine, Medicine, 030211 gastroenterology & hepatology, business
Abstract

International audience; EASL International Liver Congress, APR 13-17, 2016, Barcelona, SPAIN

Published
2016
Full Text
View/download PDF

11. Daclatasvir plus Sofosbuvir with or without Ribavirin in Patients with HCV Infection and Decompensated Cirrhosis: Interim Analysis of a French Multicentre Compassionate use Programme

Author

V. Di Martino, Frédéric Oberti, G.-P. Pageaux, D. Blaison, Fabio Conti, Eric Nguyen-Khac, D. Lacoste, Ghassan Riachi, Vincent Leroy, Christophe Hézode, Raoudha Akremi, Mariagrazia Tateo, Yacia Bennai, S. Metivier, Jean-Pierre Bronowicki, Dominique Guyader, J. Vergniol, C. Michau, Hélène Fontaine, Régine Truchi, Anne Filipovics, Epidémiologie pronostique des cancers et affections graves, Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'hépato-gastro-entérologie [APHP Henri Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre Hépato-Biliaire [Hôpital Paul Brousse] (CHB), Hôpital Paul Brousse-Assistance Publique - Hôpitaux de Paris, Centre de Recherche Saint-Antoine (UMRS893), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Groupe de Recherche sur l'alcool et les pharmacodépendances - UMR INSERM_S 1247 (GRAP), Université de Picardie Jules Verne (UPJV)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'Hépato Gastroenterologie [CHU Amiens-Picardie], CHU Amiens-Picardie, Comité de coordination Régionale de lutte contre l'infection due au Virus de l'immunodéficience Humaine, Partenaires INRAE, Service de médecine interne et maladies infectieuses [Bordeaux], CHU Bordeaux [Bordeaux]-Groupe hospitalier Saint-André, Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Centre Hospitalier Universitaire de Nice (CHU Nice), Foie, métabolismes et cancer, Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Pontchaillou [Rennes], Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Centre hospitalier de Saint-Nazaire, Centre hospitalier Troyes (CH Troyes), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Service d'hépatologie médicale [CHU Cochin], Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Bristol-Myers Squibb Company, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), CHU Toulouse [Toulouse], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), and Hôpital Charles Nicolle [Rouen]-CHU Rouen

Subjects
medicine.medical_specialty, Daclatasvir, Hepatology, Sofosbuvir, business.industry, Ribavirin, [SDV]Life Sciences [q-bio], Compassionate Use, Interim analysis, Decompensated cirrhosis, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, chemistry, 030220 oncology & carcinogenesis, Internal medicine, medicine, 030211 gastroenterology & hepatology, In patient, business, medicine.drug
Abstract

EASL International Liver Congress, Barcelona, SPAIN, APR 13-17, 2016; International audience

Published
2016
Full Text
View/download PDF

12. Long‐term outcome of chronic hepatitis C in a population‐based cohort and impact of antiviral therapy: a propensity‐adjusted analysis

Author

Patrick Hillon, Thierry Thevenot, V. Di Martino, J. Crouzet, Elisabeth Monnet, and Anne Minello

Subjects
Adult, Liver Cirrhosis, Male, medicine.medical_specialty, Carcinoma, Hepatocellular, Multivariate analysis, Cirrhosis, Adolescent, Alcohol Drinking, Population, Antiviral Agents, Gastroenterology, Polyethylene Glycols, Cohort Studies, Virology, Internal medicine, Ribavirin, medicine, Humans, education, Aged, education.field_of_study, Hepatology, business.industry, Liver Neoplasms, Interferon-alpha, Hepatitis C, Hepatitis C, Chronic, Middle Aged, medicine.disease, Recombinant Proteins, Surgery, Treatment Outcome, Infectious Diseases, Hepatocellular carcinoma, Propensity score matching, Female, Liver cancer, business, Cohort study
Abstract

This population-based study aimed to assess thedeterminants of the outcome of chronic hepatitis C withanalysis of the impact of antiviral therapy with or withoutsustained virological response (SVR) on cirrhosis decom-pensation, hepatocellular carcinoma, liver-related and non-liver-related mortality. A total of 1159 HCV-positive patientsnewly detected between 1994 and 2001 were included. Foreach outcome, the prognostic effect of patients baselinecharacteristics was estimated by time-dependent Cox modelsusing age as the time-scale and adjusting for treatmentreceived during follow-up. The impact of antiviral therapywas assessed by using a propensity score in a sampleincluding 184 patients treated in the first 24 months fol-lowing diagnosis who were matched to 184 untreatedpatients. At the end of a 59-month median follow-up, 100cases of compensated disease, 58 liver cancer and 163deaths (55 liver related) were recorded. The 5-year rates ofdecompensated cirrhosis, hepatocellular carcinoma, liver-related and non-liver-related death were 4.4%, 2.7%, 5.0%and 8.9%, respectively. Multivariate analyses identified twovariables with pejorative influence: alcohol consumption(RR = 4.29 for CD; RR = 5.76 for HCC; RR = 6.69 for liver-related death; P < 0.0001); HCV diagnosis unrelated tosystematic screening (RR = 2.25 for CD; RR = 3.05 forHCC; RR = 4.31 for liver-related death, P < 0.03). In thematched subset, no significant benefit of antiviral therapywas observed. Nevertheless, among the 144 patients whoachieved SVR, no death was observed. This population-basedstudy showed substantial rates of decompensated cirrhosis,hepatocellular carcinoma and non-liver-related mortality.Alcohol consumption and absence of systematic screeningwere significant determinants of poor outcome, whereastreatment did not have significant influence.Keywords: antiviral therapy, hepatitis C, liver-related mor-tality, non-liver-related mortality, outcome, population-based cohort study, survival bias.

Published
2011
Full Text
View/download PDF

13. P.09.17 PNPLA3 RS738409 POLYMORPHISM PREDICTS THE DEVELOPMENT AND THE SEVERITY OF HEPATIC STEATOSIS, BUT NOT METABOLIC SYNDROME, IN PATIENTS WITH CELIAC DISEASE

Author

Anna Alisi, Antonio Rispo, N. Gerbino, Valerio Nobili, Filomena Morisco, Luca Miele, Annalisa Crudele, Nicola Imperatore, Francesca Ferretti, V. Di Martino, R. Tortora, and Nicola Caporaso

Subjects
medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Gastroenterology, medicine, In patient, Disease, Steatosis, Metabolic syndrome, medicine.disease, business
Published
2018
Full Text
View/download PDF

14. Coeliac disease in chronic hepatitis C: a French multicentre prospective study

Author

Christophe Renou, Jean François Cadranel, Patrice Dumouchel, Thierry Thevenot, N. Abdelli, Elisabeth Monnet, Vincent Jouannaud, Eric Nguyen-Khac, Solange Bresson-Hadni, Jacques Denis, H. Labadie, V. Di Martino, and M. Chousterman

Subjects
medicine.medical_specialty, Cirrhosis, Hepatitis C virus, Population, Context (language use), medicine.disease_cause, Gastroenterology, Coeliac disease, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Immunopathology, medicine, Pharmacology (medical), 030212 general & internal medicine, education, Prospective cohort study, education.field_of_study, Hepatology, business.industry, medicine.disease, 3. Good health, 030211 gastroenterology & hepatology, Viral disease, business
Abstract

Summary Background A prevalence of 1.2% of coeliac disease (CD) in patients with chronic hepatitis C was recently reported, suggesting a possible epidemiological link between these two diseases. However, other studies have not found this relationship. Aim To conduct a French multicentre prospective study to assess the prevalence of CD in hepatitis C virus (HCV)-infected patients. Methods Between June 2003 and November 2005, 624 consecutive HCV-positive out-patients were tested for antiendomysial IgA antibodies (AEA), antigliadin IgA and IgG antibodies (AGA). Patients with positive AEA or IgA AGA and positive IgG AGA in a context of a high suspicion of CD were asked to undergo gastroscopy with duodenal biopsies. Results Isolated IgA AEA, IgA AGA and IgG AGA were 0.16%, 5.7% and 4.4%, respectively. Gastroscopy was required for 39 patients, 31 were performed (eight refusals), but only 25 duodenal biopsies were performed as six patients had cirrhosis. CD was never detected. Conclusions The prevalence of CD in HCV-positive patients was 0% (95% confidence interval: 0–0.59%), but there is a low prevalence of CD in the whole French population.

Published
2007
Full Text
View/download PDF

15. Continuous infusion of high-dose omeprazole is more effective than standard-dose omeprazole in patients with high-risk peptic ulcer bleeding: a retrospective study

Author

V. Di Martino, Thierry Poynard, M. Simon-Rudler, J. Massard, Dominique Thabut, V. Ratziu, and Brigitte Bernard-Chabert

Subjects
medicine.medical_specialty, Blood transfusion, medicine.drug_class, medicine.medical_treatment, Proton-pump inhibitor, Peptic Ulcer Hemorrhage, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Medicine, Pharmacology (medical), 030212 general & internal medicine, Omeprazole, Hepatology, medicine.diagnostic_test, business.industry, Anti-ulcer Agent, Retrospective cohort study, Effective dose (pharmacology), 3. Good health, Endoscopy, 030211 gastroenterology & hepatology, business, medicine.drug
Abstract

SUMMARY High-dose omeprazole reduces the rate of recurrent bleeding after endoscopic treatment of peptic ulcer bleeding. However, the effectiveness of high-dose vs. standard-dose omeprazole in peptic ulcer bleeding has never been shown. Aim To compare the benefits of high-dose vs. standard-dose omeprazole in peptic ulcer bleeding. Methods We reviewed the medical files of patients admitted between 1997 and 2004 for high-risk peptic ulcer bleeding who had undergone successful endoscopic treatment. We distinguished 2 periods: before 2001, standarddose omeprazole (40 mg ⁄ day intravenously until alimentation was possible, then 40 mg ⁄ day orally for 1 week); after 2001, high-dose omeprazole (80 mg bolus injection, then 8 mg ⁄ h continuous infusion for 72 h, then 40 mg ⁄ day orally for 1 week). During both periods, patients subsequently received omeprazole, 20 mg ⁄ day, orally for 3 weeks. Results We enrolled 114 patients (period 1, n = 45, period 2, n = 69). Therapy with high-dose omeprazole significantly decreased the occurrence of poor outcome (27 vs. 12%, P = 0.04), rebleeding (24 vs. 7%, P = 0.01), mortality due to haemorrhagic shock (11 vs. 0%, P < 0.001) and need for surgery (9 vs. 1%, P = 0.05). Conclusions In this retrospective study, high-dose omeprazole reduced the occurrence of rebleeding, need for surgery and mortality due to hemorrhagic shock in patients with high-risk peptic ulcer bleeding, as compared with standard-dose omeprazole.

Published
2007
Full Text
View/download PDF

16. O109 : Treatment of severe HCV-recurrence after liver transplantation using sofosbuvir-based regimens: The ANRS CO23 CUPILT study

Author

G.-P. Pageaux, Jean Charles Duclos-Vallée, F. Durand, L. D’Alteroche, Valérie Canva, H. Danjou, Audrey Coilly, Vincent Leroy, Danielle Botta-Fridlund, Claire Fougerou-Leurent, Pauline Houssel-Debry, Abou Diallo, Fabio Conti, Nassim Kamar, V. Di Martino, S. Radenne, Christophe Duvoux, A. Rohel, V. de Ledinghen, Jérôme Dumortier, Département d'hépatologie, Hospices Civils de Lyon (HCL), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de médecine moléculaire de Rangueil (I2MR), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)- Institut Fédératif de Recherche Bio-médicale Institution (IFR150)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département de Néphrologie et Transplantation d'organes [CHU Toulouse], Pôle Urologie - Néphrologie - Dialyse - Transplantations - Brûlés - Chirurgie plastique - Explorations fonctionnelles et physiologiques [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-IFR150-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Multiorgan Transplantation, and CHU Toulouse [Toulouse]

Subjects
medicine.medical_specialty, Hepatology, Sofosbuvir, business.industry, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Hcv recurrence, Liver transplantation, Gastroenterology, 3. Good health, Internal medicine, medicine, business, ComputingMilieux_MISCELLANEOUS, medicine.drug
Abstract

International audience; no abstract

Published
2015
Full Text
View/download PDF

17. G15 : The association of sofosbuvir and daclatasvir for treating severe recurrence of HCV infection after liver transplantation: Results from a large french prospective multicentric ANRS CO23 CUPILT cohort

Author

Nassim Kamar, Jérôme Dumortier, Pascal Lebray, P. Perré, C. Silvain, Jean Charles Duclos-Vallée, Vincent Leroy, Audrey Coilly, Valérie Canva, V. Di Martino, Alain Renault, Pauline Houssel-Debry, G.-P. Pageaux, Danielle Botta-Fridlund, H. Danjou, C. Fougerou, Sylvie Radenne, Christophe Moreno, L. D’Alteroche, V. de Ledinghen, Camille Besch, Rodolphe Anty, Christophe Duvoux, A. Rohel, Service de Pharmacologie [Rennes], CHU Pontchaillou [Rennes], Institut de médecine moléculaire de Rangueil (I2MR), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)- Institut Fédératif de Recherche Bio-médicale Institution (IFR150)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département de Néphrologie et Transplantation d'organes [CHU Toulouse], Pôle Urologie - Néphrologie - Dialyse - Transplantations - Brûlés - Chirurgie plastique - Explorations fonctionnelles et physiologiques [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Département d'hépatologie, Hospices Civils de Lyon (HCL), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-IFR150-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Multiorgan Transplantation, CHU Toulouse [Toulouse], Université de Rennes 1 (UR1), and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
medicine.medical_specialty, Daclatasvir, Hepatology, Sofosbuvir, business.industry, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Liver transplantation, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Immunology, Cohort, medicine, 030211 gastroenterology & hepatology, business, ComputingMilieux_MISCELLANEOUS, medicine.drug
Abstract

International audience; no abstract

Published
2015
Full Text
View/download PDF

18. LP05 : Daclatasvir plus sofosbuvir with or without ribavirin in patients with HCV genotype 3 infection: Interim analysis of a french multicenter compassionate use program

Author

Isabelle Rosa, V. de Ledinghen, Jean-Pierre Bronowicki, C. Silvain, Danielle Botta-Fridlund, Christophe Hézode, Yacia Bennai, Raoudha Akremi, M. Bourlière, Eric Nguyen-Khac, Pascal Lebray, I. Hubert-Fouchard, Dominique Larrey, Vincent Leroy, Hélène Fontaine, V. Di Martino, L. D’Alteroche, Dominique Guyader, Fabien Zoulim, Nathalie Boyer, Larysa Fedchuk, Fabrice Carrat, Service d'hépato-gastro-entérologie [APHP Henri Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Institut de pharmacologie moléculaire et cellulaire (IPMC), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS), Matière et Systèmes Complexes (MSC), Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), Service d'Hépato-gastroentérologie, Assistance Publique - Hôpitaux de Marseille (APHM), Service des maladies du foie [CHU Rennes], Centre Hospitalier Universitaire [Rennes], Foie, métabolismes et cancer, Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Amiens-Picardie, Groupe de Recherche sur l'alcool et les pharmacodépendances - UMR INSERM_S 1247 (GRAP), Université de Picardie Jules Verne (UPJV)-Institut National de la Santé et de la Recherche Médicale (INSERM), ESIM - Déterminants Sociaux de la Santé et du Recours aux Soins (DS3), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Hôpital Henri Mondor-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Nice Sophia Antipolis (... - 2019) (UNS), Matière et Systèmes Complexes (MSC (UMR_7057)), Centre National de la Recherche Scientifique (CNRS)-Université Paris Diderot - Paris 7 (UPD7), Service des maladies du foie, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Centre Hospitalier Universitaire [Rennes], Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), CRLCC Val d'Aurelle - Paul Lamarque-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche en Cancérologie de Lyon (CRCL), Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire [Rennes]-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou, Epidémiologie, Systèmes dínformation et modélisation (ESIM), and CHU Saint-Antoine [APHP]

Subjects
medicine.medical_specialty, Daclatasvir, Hepatology, Sofosbuvir, business.industry, Ribavirin, [SDV]Life Sciences [q-bio], Compassionate Use, Interim analysis, Virology, 3. Good health, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, chemistry, 030220 oncology & carcinogenesis, Internal medicine, Genotype, Medicine, 030211 gastroenterology & hepatology, In patient, business, ComputingMilieux_MISCELLANEOUS, medicine.drug
Abstract

International audience; no abstract

Published
2015
Full Text
View/download PDF

19. P0768 : Late mortality in treatment-experienced cirrhotic patients treated with triple therapy including boceprevir or telaprevir in a real-life cohort - ANRS Co 20 cupic

Author

Stanislas Pol, Dominique Larrey, Hélène Fontaine, Valérie Canva, A. Tran, Christophe Hézode, Armando Abergel, Yoann Barthe, Laurent Alric, Thong Dao, Pierre Attali, J.-M. Pawlotsky, Damien Lucidarme, Didier Samuel, Patrice Cacoub, S. Metivier, Thierry Poynard, Paul Calès, V. de Ledinghen, Véronique Loustaud-Ratti, M. Bourlière, Isabelle Rosa, Fabrice Carrat, Véronique Grando-Lemaire, Fabien Zoulim, V. Di Martino, C. Dufour, Ghassan Riachi, Pierre-Henri Bernard, Jean-Pierre Bronowicki, Isabelle Portal, Lawrence Serfaty, T. Fontanges, Patrick Marcellin, J.-J. Raabe, Dominique Guyader, Xavier Causse, Jean-Pierre Zarski, Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre de recherche sur les Ions, les MAtériaux et la Photonique (CIMAP - UMR 6252), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-École Nationale Supérieure d'Ingénieurs de Caen (ENSICAEN), Normandie Université (NU)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche sur les Matériaux Avancés (IRMA), Normandie Université (NU)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université de Rouen Normandie (UNIROUEN), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Service d'hépatologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'Hépato-gastroentérologie, Assistance Publique - Hôpitaux de Marseille (APHM), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut d'astrophysique spatiale (IAS), Université Paris-Sud - Paris 11 (UP11)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-Centre National d’Études Spatiales [Paris] (CNES), Service des maladies du foie [CHU Rennes], Centre Hospitalier Universitaire [Rennes], Foie, métabolismes et cancer, Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Pitié-Salpêtrière [AP-HP], SFR UA 4208 Interactions Cellulaires et Applications Thérapeutiques (ICAT), Université d'Angers (UA), Centre Hospitalier Universitaire de Nice (CHU Nice), Service d'hépatologie médicale [CHU Cochin], Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), ESIM - Déterminants Sociaux de la Santé et du Recours aux Soins (DS3), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de Recherche en Cancérologie de Montpellier ( IRCM - U1194 Inserm - UM ), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Montpellier ( UM ), Centre de recherche sur les Ions, les MAtériaux et la Photonique ( CIMAP - UMR 6252 ), Centre National de la Recherche Scientifique ( CNRS ) -Ecole Nationale Supérieure d'Ingénieurs de Caen ( ENSICAEN ), Normandie Université ( NU ) -Normandie Université ( NU ) -Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Université de Caen Normandie ( UNICAEN ), Normandie Université ( NU ), Centre de Recherche en Cancérologie de Lyon ( CRCL ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Institut de biologie et chimie des protéines [Lyon] ( IBCP ), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique ( CNRS ), Assistance publique - Hôpitaux de Paris (AP-HP)-Université Paris Diderot - Paris 7 ( UPD7 ) -Hôpital Beaujon, Assistance Publique - Hôpitaux de Marseille ( APHM ), Service d'hépatologie [Saint-Antoine], Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Saint-Antoine [APHP], Institut d'astrophysique spatiale ( IAS ), Université Paris-Sud - Paris 11 ( UP11 ) -Institut national des sciences de l'Univers ( INSU - CNRS ) -Centre National de la Recherche Scientifique ( CNRS ), Service des maladies du foie, Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Hôpital Pontchaillou-Centre Hospitalier Universitaire de Rennes, Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Pitié-Salpêtrière [APHP], Interactions cellulaires et applications thérapeutiques ( ICAT ), Université d'Angers ( UA ) -CHU Angers-CRLCC Paul Papin-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), CIRAD, UPR AGIRs, Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP], Epidémiologie, Systèmes dínformation et modélisation ( ESIM ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Unité de Santé Publique, Assistance publique - Hôpitaux de Paris - AP-HP (FRANCE)-CHU Saint-Antoine [APHP], Centre National de la Recherche Scientifique (CNRS)-École Nationale Supérieure d'Ingénieurs de Caen (ENSICAEN), Normandie Université (NU)-Normandie Université (NU)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université de Caen Normandie (UNICAEN), Normandie Université (NU), Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Université Paris-Sud - Paris 11 (UP11)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Centre Hospitalier Universitaire [Rennes], Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Normandie Université (NU)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Service d'hépatologie [CHU Saint-Antoine], Centre Hospitalier Universitaire [Rennes]-Université de Rennes 1 (UR1), and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou

Subjects
0303 health sciences, Pediatrics, medicine.medical_specialty, Hepatology, [ SDV ] Life Sciences [q-bio], business.industry, [SDV]Life Sciences [q-bio], Treatment experienced, 3. Good health, Telaprevir, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, chemistry, Boceprevir, Cohort, medicine, 030211 gastroenterology & hepatology, business, ComputingMilieux_MISCELLANEOUS, 030304 developmental biology, medicine.drug
Abstract

International audience; no abstract

Published
2015
Full Text
View/download PDF

20. Flumazenil vs. placebo in hepatic encephalopathy in patients with cirrhosis: a meta-analysis

Author

Thierry Poynard, Jean François Cadranel, C. Goulenok, V. Di Martino, Dominique Thabut, B Bernard, and Pierre Opolon

Subjects
Cirrhosis, Hepatology, business.industry, Encephalopathy, Gastroenterology, Odds ratio, medicine.disease, Placebo, Confidence interval, law.invention, Randomized controlled trial, Flumazenil, law, Anesthesia, medicine, Pharmacology (medical), business, Hepatic encephalopathy, medicine.drug
Abstract

Background: Randomized controlled trials testing flumazenil in hepatic encephalopathy have shown conflicting results. Aim: To compare flumazenil and placebo in hepatic encephalopathy in patients with cirrhosis. Methods: An overview of randomized controlled trials comparing flumazenil and placebo in hepatic encephalopathy in patients with cirrhosis was performed. For each end-point, heterogeneity and treatment efficacy were assessed by Peto and Der Simonian methods. As most trials were crossover in nature, a sensitivity analysis was performed including the two treatment periods. Results: Six double-blind randomized controlled trials, including 641 patients (326 treated with flumazenil and 315 with placebo), were identified. The treatment duration ranged from 5 min to 3 days. Heterogeneity tests between control groups were not significant. The mean percentages of patients with clinical improvement (five trials) were 27% in treated groups and 3% in placebo groups. This difference was significant by both methods (Peto: odds ratio=6.15; 95% confidence interval, 4.0–9.5; P

Published
2002
Full Text
View/download PDF

21. A randomized trial of 6-month norfloxacin therapy in patients with Child-Pugh class C cirrhosis

Author

Frédéric Oberti, V. Di Martino, L. Elkrief, Rodolphe Anty, Didier Lebrec, Thierry Thevenot, Richard Moreau, Nathalie Gault, Jean-Marc Perarnau, Marie-Angèle Robic, Isabelle Ollivier-Hourmand, L. D’Alteroche, Pierre-Emmanuel Rautou, Blandine Pasquet, Alexandre Louvet, Violaine Ozenne, C. Bureau, Sophie Hillaire, Marika Rudler, Faouzi Saliba, and P. Nahon

Subjects
medicine.medical_specialty, Cirrhosis, Hepatology, business.industry, medicine.disease, Gastroenterology, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, 030220 oncology & carcinogenesis, Internal medicine, Medicine, 030211 gastroenterology & hepatology, Child-Pugh Class C, In patient, business, Norfloxacin, medicine.drug
Published
2017
Full Text
View/download PDF

22. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients

Author

François Bricaire, Thierry Poynard, F. Azria, Yves Benhamou, Frédéric Charlotte, V. Di Martino, Pierre Opolon, Michel Vidaud, Anne Coutellier, Marie Bochet, and Christine Katlama

Subjects
medicine.medical_specialty, Hepatology, business.industry, medicine.medical_treatment, Hepatitis C virus, virus diseases, Immunosuppression, medicine.disease_cause, medicine.disease, Gastroenterology, digestive system diseases, Serology, Fibrosis, Internal medicine, Immunopathology, Immunology, medicine, Viral disease, Risk factor, Prospective cohort study, business
Abstract

The natural history of hepatitis C virus (HCV) infection in human immunodeficiency virus (HIV)-infected patients has never been studied according to the concept of liver fibrosis progression. The aim of this work was to assess the fibrosis progression rate in HIV-HCV coinfected patients and in patients infected by HCV only. A cohort of 122 HIV-HCV coinfected patients was compared with a control group of 122 HIV-negative HCV-infected patients. Groups were matched according to age, sex, daily alcohol consumption, age at HCV infection, and duration and route of HCV infection. The fibrosis progression rate was defined as the ratio between fibrosis stage (METAVIR scoring system) and the HCV duration. The prevalence of extensive liver fibrosis (METAVIR fibrosis scores 2, 3, and 4) and moderate or severe activity were higher in HIV-infected patients (60% and 54%, respectively) than in control patients (47% and 30%, respectively; P 50 g/d, P =.0002), age at HCV infection ( 50 g/d), CD4 count (

Published
1999
Full Text
View/download PDF

23. Cyamamezine-induced acute hepatitis after unique massive intake

Author

A. Cazier, V Pras, Philippe Bonnard, Bruno Devergie, M. Biour, V Di Martino, and Jean François Cadranel

Subjects
Adult, medicine.medical_specialty, Victimology, Suicide, Attempted, Cyamemazine, chemistry.chemical_compound, Phenothiazines, Internal medicine, Pharmacovigilance, medicine, Humans, Chlorpromazine, Hepatitis, Hepatology, Suicide attempt, business.industry, Gastroenterology, medicine.disease, Surgery, Liver, chemistry, Acute Disease, Toxicity, Etiology, Female, Chemical and Drug Induced Liver Injury, business, medicine.drug
Abstract

Hepatotoxicity of cyamamezine, a phenothiazine structurally related to chlorpromazine, has been rarely documented. We report here a case of acute symptomatic hepatitis following a unique massive intake of cyamamezine in a suicide attempt and discuss the mechanisms of such injury.

Published
1999
Full Text
View/download PDF

24. P0821 : Are extended durations and/or ribavirin useful for genotype 1 (G1) cirrhotic patients who receive DAAs combination? A meta-analysis of randomized controlled trials (RCTS)

Author

J.-P. Cervoni, C. Richou, V. Di Martino, Delphine Weil, Claire Vanlemmens, and Thierry Thevenot

Subjects
medicine.medical_specialty, Hepatology, business.industry, Ribavirin, Surgery, law.invention, chemistry.chemical_compound, chemistry, Randomized controlled trial, law, Meta-analysis, Internal medicine, Genotype, medicine, business
Published
2015
Full Text
View/download PDF

25. P0205 : Management of gastric varices: A french national survey

Author

C. Bureau, J.-P. Cervoni, Paul Castellani, V. Di Martino, N. Fares, Thierry Thevenot, Dominique Thabut, Thong Dao, Arnaud Pauwels, Frédéric Oberti, Nicolas Carbonell, Aurélie Plessier, Delphine Weil, and Marika Rudler

Subjects
medicine.medical_specialty, Hepatology, business.industry, General surgery, medicine, Gastric varices, medicine.disease, business
Published
2015
Full Text
View/download PDF

26. P0142 : Mortality risk factors in cirrhotic patients in Intensive Care Unit: A monocentric retrospective study at Besançon’s University Hospital from 2002 to 2014

Author

Gilles Capellier, J.-P. Cervoni, Gaël Piton, Claire Chaignat, C. Patry, and V. Di Martino

Subjects
medicine.medical_specialty, Hepatology, business.industry, law, Emergency medicine, medicine, Retrospective cohort study, business, University hospital, Intensive care unit, law.invention
Published
2015
Full Text
View/download PDF

27. P0132 : External validation of the CLIF-SOFA in cirrhotic patients admitted to intensive care units (ICUS): A meta-analysis

Author

Evangelos Cholongitas, Bertrand Sauneuf, J. Fichet, Constantine J. Karvellas, V. Di Martino, René Robert, Eric Levesque, Thierry Thevenot, Gilles Capellier, H.-C. Pan, Arnaud Galbois, Rodrigo Cavallazzi, Mark J. W. McPhail, Delphine Weil, Eleni Theocharidou, and Gaël Piton

Subjects
medicine.medical_specialty, Hepatology, business.industry, Clif sofa, Intensive care, Meta-analysis, Emergency medicine, External validation, medicine, business, Intensive care medicine
Published
2015
Full Text
View/download PDF

28. Long-term longitudinal study of intrahepatic hepatitis C virus replication after liver transplantation

Author

H. Bismuth, Michel Reynes, V. Di Martino, Cyrille Feray, F Saurini, Elisabeth Dussaix, Michelle Gigou, and Didier Samuel

Subjects
Adult, Male, Cirrhosis, medicine.medical_treatment, Hepatitis C virus, Hepacivirus, Liver transplantation, medicine.disease_cause, Virus Replication, Virus, medicine, Humans, Longitudinal Studies, Postoperative Period, Hepatitis, biology, Dose-Response Relationship, Drug, Hepatology, Hepatitis C, Hepatitis C, Chronic, Middle Aged, medicine.disease, biology.organism_classification, Prognosis, Virology, Liver Transplantation, Transplantation, Liver, Disease Progression, Prednisone, RNA, Viral, Female
Abstract

Recurrence of hepatitis C after liver transplantation is common and can lead to severe liver diseases. Although immunosuppression and high levels of viremia suggest a direct pathogenicity of hepatitis C virus (HCV), the relations between viral replication and long-term histological course are still unknown. Thirty-three patients with a mean histological follow-up of 3.5 years (3 months - 8.6 years) were analyzed. Nineteen patients were infected by genotype 1b. Liver HCV RNA was determined in parallel with the quantitation of an internal control (28S ribosomal RNA) by competitive polymerase chain reaction (PCR). Lobular hepatitis (LH) and chronic active hepatitis (CAH) occurred in 27 and 19 patients, respectively. Levels of liver HCV RNA determined in 84 biopsies were higher in cases of LH than in the other patterns (82 +/- 123 vs. 19 +/- 38; P.01) and were unrelated to the genotype. Progression from LH to CAH was associated with a highly significant decrease of liver HCV RNA (P = .006), which was not observed in patients with stable histology. Among patients with CAH, those infected by genotype 1b had more severe liver damage and lower levels of liver HCV RNA than others (P = .04). Multivariate analysis showed that high levels of liver HCV RNA at the time of the first posttransplantation biopsy was an independent predictor of CAH (P = .01). After liver transplantation, the progression to CAH together with a decrease of liver HCV RNA suggests that a host's response is involved in the long-term viral pathogenicity. This response may be stronger and liver disease more severe in patients with high levels of replication at the time of LH and in those infected by genotype 1b.

Published
1997
Full Text
View/download PDF

29. Nicardipine as antihypertensive therapy in liver transplant recipients: Results of long-term use

Author

Pierre-Louis Fagniez, Métreau Jm, Christophe Duvoux, Salvat A, Daniel Cherqui, Lauzet Jy, V. Di Martino, and Daniel Dhumeaux

Subjects
Chemotherapy, medicine.medical_specialty, Hepatology, business.industry, medicine.drug_class, medicine.medical_treatment, Nicardipine, Urology, Calcium channel blocker, Liver transplantation, Transplantation, Prednisone, Anesthesia, Toxicity, medicine, business, Postoperative Hypertension, medicine.drug
Abstract

Arterial hypertension is frequent in liver transplant recipients on cyclosporine A (CsA). Nicardipine is a calcium channel blocker (CCB) that has been shown to be efficient in controlling postoperative hypertension. However, its use has been limited in organ recipients because of its reported interaction with CsA metabolism. In this report, we studied the results of the long-term use of nicardipine after liver transplantation. Forty-nine consecutive liver transplant recipients with a follow-up longer than 2 years were studied. Immunosuppressive regimen was based on CsA and prednisone. Patients with immediate postoperative hypertension received intravenous nicardipine, secondarily switched to oral nicardipine (group 1, n = 27). Patients with delayed hypertension (i.e., >2 weeks posttransplant) received other antihypertensive drugs which did not interact with CsA metabolism. These patients and those without hypertension formed group 2 (n = 22). The two groups were similar for age, sex, body weight, and transplantation indications. Interaction of nicardipine with CsA metabolism was confirmed. Whereas cyclosporine blood levels were similar in both groups at any time during the study, the mean cyclosporine daily dose required to achieve such levels was 30% lower in group 1 compared with group 2 (P < .01). This resulted in a significant cost-containment. The use of nicardipine was not associated with an increased incidence of graft rejection or CsA toxicity episodes. The results in liver transplant recipients showed that nicardipine interacts with CsA metabolism, leading to a 30% reduction in CsA dose and does not increase the risk of CsA toxicity or graft rejection. Nicardipine can be used safely for the treatment of arterial hypertension after liver transplantation with a potential cost-containment.

Published
1997
Full Text
View/download PDF

30. Renal Dysfunction in Liver Transplant Patients Treated with Sofosbuvir Based-Regimen for HCV Recurrence: Results from a Large French Prospective Multicentric ANRS CO23 Cupilt

Author

A. Rohel, Sébastien Dharancy, Pascal Lebray, S. Radenne, C. Silvain, Christophe Duvoux, V. Di Martino, G.-P. Pageaux, V. de Ledinghen, Camille Besch, Nassim Kamar, Emilie Rossignol, François Habersetzer, Jean Charles Duclos-Vallée, Christophe Moreno, Rodolphe Anty, Alain Renault, H. Danjou, F. Durand, Valérie Canva, Guillaume Favre, Pauline Houssel-Debry, L. D’Alteroche, H. Montialoux, Jérôme Dumortier, Audrey Coilly, Vincent Leroy, C. Fougerou, A. Tran, and Danielle Botta-Fridlund

Subjects
medicine.medical_specialty, Hepatology, Sofosbuvir, business.industry, Hcv recurrence, Gastroenterology, 03 medical and health sciences, Regimen, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Medicine, 030211 gastroenterology & hepatology, Transplant patient, business, medicine.drug
Published
2016
Full Text
View/download PDF

31. Sofosbuvir-Based-Regimen for HCV Recurrence after Combined Liver-Kidney Transplantation : Results from the ANRS CO23 Cupilt Study

Author

V. Di Martino, P. Perré, A. Tran, François Habersetzer, Danielle Botta-Fridlund, C. Silvain, L. D’Alteroche, G.-P. Pageaux, Claire Fougerou-Leurent, H. Montialoux, Vincent Leroy, Jérôme Dumortier, Audrey Coilly, Christophe Duvoux, V. de Ledinghen, Pauline Houssel-Debry, Camille Besch, Maryline Debette-Gratien, S. Radenne, Nassim Kamar, Jean-Charles Duclos Vallee, Valérie Canva, Armando Abergel, Christophe Moreno, Sébastien Dharancy, Fabio Conti, Claire Francoz, and A. Rohel

Subjects
medicine.medical_specialty, Liver kidney transplantation, Hepatology, Sofosbuvir, business.industry, Hcv recurrence, Gastroenterology, 03 medical and health sciences, Regimen, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, medicine, 030211 gastroenterology & hepatology, business, medicine.drug
Published
2016
Full Text
View/download PDF

32. P455 BACTERIAL ENDOCARDITIS IN PATIENTS WITH CIRRHOSIS: A MULTICENTER RETROSPECTIVE STUDY OF 78 CASES

Author

C. Bureau, Hervé Hagège, C. Chagneau-Derrode, A. Viennot, Teresa Antonini, Isabelle Ollivier-Hourmand, Vincent Jouannaud, Christine Silvain, V. Di Martino, G. Le Folgoc, M. Bourlière, Jean François Cadranel, B. Lesgourgues, Jean-Marie Péron, E. Sarlon, Hélène Blasco-Perrin, Jean-Didier Grangé, Thong Dao, M. Bakkar, R. Arotcarena, Xavier Adhoute, Manon Allaire, Thierry Thevenot, Didier Samuel, K. Dupont, Jean-Baptiste Nousbaum, Jacques Denis, Armand Garioud, Hortensia Lison, E. A. Pariente, I. Rosa-Hézode, and Xavier Causse

Subjects
medicine.medical_specialty, Cirrhosis, Hepatology, Bacterial endocarditis, business.industry, Internal medicine, medicine, Retrospective cohort study, In patient, medicine.disease, business
Published
2014
Full Text
View/download PDF

33. P0149 : Six-month mortality of cirrhotic patients who survived intensive care: A meta-analysis

Author

Mark J. W. McPhail, Delphine Weil, Rodrigo Cavallazzi, Bertrand Sauneuf, Gaël Piton, J. Fichet, René Robert, Constantine J. Karvellas, Evangelos Cholongitas, Thierry Thevenot, Gilles Capellier, H.-C. Pan, Arnaud Galbois, V. Di Martino, Eric Levesque, and Eleni Theocharidou

Subjects
medicine.medical_specialty, Hepatology, business.industry, Intensive care, Meta-analysis, Emergency medicine, medicine, business
Published
2015
Full Text
View/download PDF

35. P0150 : Liver cirrhosis is independently associated with mortality in patients with bacterial endocarditis: Results of a case control multicenter study of 202 cases

Author

Manon Allaire, I. Rosa-Hézode, C. Chagneau-Derrode, Jean-Didier Grangé, V. Di Martino, Teresa Antonini, H. Hagège, Laurent Alric, Jérôme Dumortier, Jacques Denis, Isabelle Ollivier-Hourmand, A. Pelaquier, M. Hattab, Patrice Cacoub, P. Mathurin, Thierry Thevenot, K. Dupont, Jean-Marie Péron, M. Bakar, Xavier Amiot, Pierre Iaria, Jean François Cadranel, Gilles Macaigne, Xavier Adhoute, J. Gournay, Jean-Claude Trinchet, Hélène Blasco-Perrin, Jean-Baptiste Nousbaum, Alexandre Pariente, M. Bourlière, Didier Samuel, Christine Silvain, Thong Dao, B. Lesgourgues, Nathalie Ganne-Carrié, Jean-Pierre Bronowicki, Armand Garioud, Hortensia Lison, Salah Zerkly, L. Spahr, Xavier Causse, Alexandre Louvet, Vincent Jouannaud, C. Bureau, and R. Chentouh

Subjects
medicine.medical_specialty, Cirrhosis, Hepatology, Multicenter study, Bacterial endocarditis, business.industry, Internal medicine, medicine, In patient, business, medicine.disease, Surgery
Published
2015
Full Text
View/download PDF

36. 765 TWELVE-MONTHS ENTECAVIR LONGITUDINAL CHANGES IN LIVER FIBROSIS, ACTIVITY AS PER FibroTest-FibroMax AND LIVER STIFFNESS MEASUREMENTS IN CHRONIC HEPATITIS B. STEATOSIS IMPACT ON FIBROSIS REGRESSION

Author

Fabien Zoulim, V. Di Martino, Marika Rudler, Dominique Thabut, J. Massard, V. de Ledinghen, Jean-Pierre Bronowicki, L. Bonyhay, Christophe Renou, Nathalie Ganne, Joseph Moussalli, F. Dranne, Yen Ngo, Vincent Leroy, Mona Munteanu, V. Bourcier, Xavier Causse, Denis Ouzan, Thierry Poynard, Raluca Pais, and P. Mathurin

Subjects
medicine.medical_specialty, Hepatology, FibroTest, business.industry, Liver fibrosis, Entecavir, medicine.disease, Gastroenterology, Chronic hepatitis, Liver stiffness, Fibrosis, Internal medicine, medicine, Steatosis, business, medicine.drug
Published
2013
Full Text
View/download PDF

37. 712 PNPLA 3 RS738409 GG HOMOZYGOTE STATUS IS ASSOCIATED WITH INCREASED RISK OF HEPATOCELLULAR CARCINOMA IN CIRRHOTIC PATIENTS

Author

Bruno Vergès, Boris Guiu, David Masson, Christine Binquet, C. Bonithon Kopp, C. Richou, Patrick Hillon, Jean-Pierre Bronowicki, Hélène Barraud, Jean-Louis Jouve, V. Di Martino, G. Thieffin, Samia Hamza, Michel Doffoel, J.J. Raab, Jean-Marie Petit, Catherine Sgro, Valérie Jooste, Anne Marie Bouvier, Vanessa Cottet, and Anne Minello

Subjects
medicine.medical_specialty, Increased risk, Hepatology, business.industry, Hepatocellular carcinoma, Internal medicine, medicine, medicine.disease, business, Gastroenterology
Published
2012
Full Text
View/download PDF

38. O69 ALBUMIN INFUSION FOR BACTERIAL INFECTIONS OTHER THAN SPONTANEOUS BACTERIAL PERITONITIS IN CIRRHOTIC PATIENTS: A MULTICENTER RANDOMIZED CONTROLLED STUDY (ALB-CIRINF STUDY)

Author

Isabelle Rosa, Aurélie Plessier, V. Di Martino, C. Bureau, Eric Nguyen-Khac, Marika Rudler, Alexandre Louvet, Rodolphe Anty, V. de Ledinghen, Thierry Paupard, Thierry Thevenot, Odile Goria, Alexandra Heurgué-Berlot, Roland Amathieu, N. Abdelli, Elisabeth Monnet, N. Talbodec, Anne Minello, Violaine Ozenne, Frédéric Oberti, Hélène Barraud, Nicolas Carbonell, Thong Dao, D. Botta-Fridlung, F. Guillemot, Xavier Causse, and C. Becker

Subjects
medicine.medical_specialty, Hepatology, business.industry, Albumin, medicine.disease, Gastroenterology, law.invention, Surgery, Spontaneous bacterial peritonitis, Randomized controlled trial, law, Internal medicine, Medicine, business
Published
2014
Full Text
View/download PDF

39. P469 COPEPTIN IS AN INDEPENDENT PROGNOSTIC FACTOR IN LIVER CIRRHOSIS

Author

Delphine Weil, Annarein J. C. Kerbert, Hein W. Verspaget, B. van Hoek, V. Di Martino, José-Philippe Moreno, Minneke J. Coenraad, and Thierry Thevenot

Subjects
medicine.medical_specialty, Prognostic factor, Cirrhosis, Copeptin, Hepatology, business.industry, Internal medicine, Medicine, business, medicine.disease, Gastroenterology
Published
2014
Full Text
View/download PDF

40. P.13.13 COLONOSCOPY PREPARATION: ELECTROLYTE FREE PEG WITH GATORADE IS AS SAFE AND EFFICACIOUS AS FOUR LITERS OF POLYETHYLENE GLYCOL WITH BALANCED ELECTROLYTES. A MULTICENTER OBSERVATIONAL TRIAL

Author

D. Cattaneo, V. Di Martino, R. Bozzi, T. Luisi, and A. Inzirillo

Subjects
medicine.medical_specialty, Hepatology, medicine.diagnostic_test, Observational Trial, business.industry, Gastroenterology, Colonoscopy, Polyethylene glycol, Electrolyte, Surgery, chemistry.chemical_compound, chemistry, Anesthesia, PEG ratio, medicine, business
Published
2014
Full Text
View/download PDF

41. 1001 PRAGMATIC ASSESSMENT OF LIVER FIBROSIS DURING METHOTREXATE THERAPY: COMPARISON OF PATIENTS WITH PSORIASIS, RHEUMATOID ARTHRITIS OR CROHN'S DISEASE

Author

Eric Toussirot, V. Bague, V. Di Martino, Paul Calès, Daniel Wendling, M. Nachury, I. Mermet, Elisabeth Monnet, Franck Carbonnel, J.-P. Cervoni, François Aubin, B. Alby-Lepresle, and E. Bertolini

Subjects
medicine.medical_specialty, Crohn's disease, Hepatology, business.industry, Liver fibrosis, medicine.disease, Gastroenterology, Internal medicine, Psoriasis, Rheumatoid arthritis, medicine, Methotrexate, business, medicine.drug
Published
2010
Full Text
View/download PDF

42. Hepatitis C virus and the host: An imbalance induced by immunosuppression?

Author

Patrick Marcellin, V. Di Martino, Thierry Thevenot, Françoise Degos, and Nathalie Boyer

Subjects
Immunosuppression Therapy, Reoperation, Hepatology, business.industry, Human immunodeficiency virus (HIV), medicine.disease_cause, Virus Replication, Virology, Hepatitis C, Liver Transplantation, Chronic hepatitis, medicine, Alanine transaminase level, Humans, RNA, Viral, Viremia, business, Interferon alfa, medicine.drug
Published
2000

44. 600 SHORTENED COURSE OF THERAPY FOR CHRONIC HEPATITIS C GENOTYPE 1 (G1) PATIENTS DEVELOPING RAPID VIROLOGICAL RESPONSE (RVR): META- ANALYSIS OF RANDOMIZED CONTROLLED TRIALS (RCTS)

Author

C. Richou, J.-P. Cervoni, V. Di Martino, and Thierry Thevenot

Subjects
Virological response, medicine.medical_specialty, Hepatology, Randomized controlled trial, Chronic hepatitis, law, business.industry, Internal medicine, Meta-analysis, Genotype, medicine, business, law.invention
Published
2009
Full Text
View/download PDF

46. [554] VARIATION OF HEPATITIS C (HC) DETECTION RATE IN A FRENCH POPULATION ACCORDING TO SOCIO-ECONOMIC CONTEXT AND DISTANCE TO MEDICAL CARE

Author

V. Di Martino, J.P. Miguel, Patrick Hillon, Philippe Evrard, Didier Carel, Anne Minello, Elisabeth Monnet, Estelle Collin, Cécile Ramée, and Valérie Jooste

Subjects
education.field_of_study, Hepatology, business.industry, Population, Context (language use), Hepatitis C, medicine.disease, Medical care, Variation (linguistics), Medicine, Medical emergency, Detection rate, business, education, Demography
Published
2007
Full Text
View/download PDF

47. 923 EMERGENCE OF A NEW OPPORTUNISTIC INFECTION IN EUROPE: HEPATIC ALVEOLAR ECHINOCOCCOSIS. A FIFTY-CASE REPORT

Author

Eric Delabrousse, Jenny Knapp, V. Di Martino, S. Capelle, Adrien Chauchet, Dominique-Angèle Vuitton, Solange Bresson-Hadni, Oleg Blagosklonov, C. Richou, Frédéric Grenouillet, E. Deconinck, and Charlotte Dentan

Subjects
medicine.medical_specialty, Hepatology, business.industry, Opportunistic infection, General surgery, Medicine, Alveolar echinococcosis, business, medicine.disease, University hospital, Hepatic Alveolar Echinococcosis, Echinococcosis, Surgery
Abstract

923 EMERGENCE OF A NEW OPPORTUNISTIC INFECTION IN EUROPE: HEPATIC ALVEOLAR ECHINOCOCCOSIS. A FIFTY-CASE REPORT A. Chauchet, F. Grenouillet, J. Knapp, C. Richou, E. Delabrousse, C. Dentan, S. Capelle, V. Di Martino, E. Deconinck, O. Blagosklonov, D.A. Vuitton, S. Bresson-Hadni, FrancEchino Network. WHO-Collaborating Centre for Prevention and Treatment of Human Echinococcosis and French National Reference Centre on Alveolar Echinococcosis, Franche-Comte University and University Hospital, Department of Hematology, Besancon University Hospital, UMR 6249 Chrono-Environnement, Besancon, Department of Rheumatology, University Hospital Grenoble, Grenoble, EA 3186, Franche Comte University, EA 3181, Franche-Comte University, Besancon, France E-mail: dr.bresson.hadni@wanadoo.fr

Published
2013
Full Text
View/download PDF

48. 148 Impact of liver transplantation (LT) on survival of pugh B alcoholic cirrhotic patients: A multicenter randomized study

Author

G. Mantion, Jean-Philippe Miguet, Claire Vanlemmens, Anne Minello, Chantal Milan, Patrick Hillon, Solange Bresson-Hadni, V. Di Martino, Christophe Duvoux, M. Messner, and Jean-Marc Perarnau

Subjects
medicine.medical_specialty, Hepatology, Randomized controlled trial, law, business.industry, Internal medicine, medicine.medical_treatment, medicine, Liver transplantation, business, Gastroenterology, law.invention
Published
2004
Full Text
View/download PDF

49. Is expansion of criteria for liver transplantation of patients with hepatocellular carcinoma possible? Lessons from a long-term follow-up cohort study assessing predictors of recurrence and mortality

Author

Bernadette Kantelip, G. Mantion, Becker Mc, Patrick Hillon, A. Franza-Minello, V. Di Martino, Elisabeth Monnet, S. Le Calvez, Jean-Philippe Miguet, and Bruno Heyd

Subjects
Oncology, medicine.medical_specialty, Pediatrics, Hepatology, business.industry, Long term follow up, medicine.medical_treatment, Liver transplantation, medicine.disease, Internal medicine, Hepatocellular carcinoma, Medicine, business, Cohort study
Published
2003
Full Text
View/download PDF

50. 1156 USE OF EPOETIN BETA IN HEPATITIS C PATIENTS: SAFETY DATA FROM THE FRENCH TRIAL NEOS - INTERIM ANALYSIS AT SIX MONTHS

Author

V. Di Martino, Jean-Pierre Bronowicki, Françoise Roudot-Thoraval, M. Bourlière, Dominique Larrey, Albert Tran, Dominique Guyader, S. Rouanet, François Habersetzer, Sophie Metivier, and V. Cartier

Subjects
medicine.medical_specialty, Epoetin beta, Hepatology, business.industry, Internal medicine, Medicine, Hepatitis C, business, Interim analysis, medicine.disease, Surgery
Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results